Alimera Sciences, Inc. (ALIM): Price and Financial Metrics


Alimera Sciences, Inc. (ALIM): $1.90

0.01 (+0.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALIM Stock Summary

  • ALIMERA SCIENCES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 3.62% of US listed stocks.
  • With a one year PEG ratio of 0.14, ALIMERA SCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 2.34% of US stocks.
  • ALIM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 3.29% of US stocks.
  • Stocks that are quantitatively similar to ALIM, based on their financial statements, market capitalization, and price volatility, are FALC, DESP, CMCM, CLRO, and NH.
  • Visit ALIM's SEC page to see the company's official filings. To visit the company's web site, go to www.alimerasciences.com.

ALIM Valuation Summary

  • In comparison to the median Healthcare stock, ALIM's price/sales ratio is 89.47% lower, now standing at 0.2.
  • ALIM's price/sales ratio has moved NA NA over the prior 157 months.

Below are key valuation metrics over time for ALIM.

Stock Date P/S P/B P/E EV/EBIT
ALIM 2023-03-24 0.2 -0.5 -0.5 -3.7
ALIM 2023-03-23 0.2 -0.6 -0.5 -3.8
ALIM 2023-03-22 0.2 -0.5 -0.5 -3.7
ALIM 2023-03-21 0.2 -0.6 -0.6 -3.9
ALIM 2023-03-20 0.2 -0.6 -0.6 -3.9
ALIM 2023-03-17 0.2 -0.6 -0.6 -3.9

ALIM Growth Metrics

    Its 5 year cash and equivalents growth rate is now at -54.15%.
  • Its year over year revenue growth rate is now at 25.71%.
  • Its 3 year price growth rate is now at -71.58%.
Over the past 15 months, ALIM's revenue has gone down $5,105,000.

The table below shows ALIM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 54.059 -14.407 -18.433
2022-06-30 52.614 -15.226 -17.359
2022-03-31 59.713 -6.936 -6.679
2021-12-31 59.029 -3.224 -4.372
2021-09-30 58.844 1.196 -1.243
2021-06-30 59.164 1.78 2.322

ALIM Price Target

For more insight on analysts targets of ALIM, see our ALIM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.83 Average Broker Recommendation 1.5 (Moderate Buy)

ALIM Stock Price Chart Interactive Chart >

Price chart for ALIM

ALIM Price/Volume Stats

Current price $1.90 52-week high $7.92
Prev. close $1.89 52-week low $1.30
Day low $1.90 Volume 1,895
Day high $1.94 Avg. volume 21,506
50-day MA $2.21 Dividend yield N/A
200-day MA $4.32 Market Cap 13.29M

Alimera Sciences, Inc. (ALIM) Company Bio


Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.


ALIM Latest News Stream


Event/Time News Detail
Loading, please wait...

ALIM Latest Social Stream


Loading social stream, please wait...

View Full ALIM Social Stream

Latest ALIM News From Around the Web

Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.

Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility

Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000Completes $12 million private placement of preferred stock and warrants with conversion price and exercise price at 55% premium to the closing share price on March 24, 2023Extends maturity of existing credit facility to April 2028 and interest-only period up to 3 years ATLANTA, March 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical

Yahoo | March 27, 2023

Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update

Conference Call to be held Friday, March 31, at 9:00am Eastern TimeATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2022 financial results on Friday, March 31, 2023, before the market opens. Management will host a confer

Yahoo | March 24, 2023

Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors

ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhney, M.D. to its Board of Directors. Dr. Sawhney is presently the Chief Financial Officer for Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies. Dr. Sawhn

Yahoo | February 27, 2023

Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®

Switzerland is latest market for Alimera in continued geographic expansionATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that its distribution partner, Horus Pharma S.A.S. (Horus) through its Swiss affiliate Horus Pharma Suisse SA, has filed a marketing authorization appl

Yahoo | February 22, 2023

Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer

Russel Skibsted 2MB Russell Skibsted, CFO of Alimera Sciences Russell Skibstead Hi-Res Russell Skibsted, CFO of Alimera Sciences ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President

Yahoo | January 9, 2023

Read More 'ALIM' Stories Here

ALIM Price Returns

1-mo -11.63%
3-mo -29.89%
6-mo -62.60%
1-year -63.67%
3-year -47.37%
5-year -87.70%
YTD -29.89%
2022 -47.17%
2021 21.56%
2020 -44.33%
2019 -29.62%
2018 -46.02%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7425 seconds.